Development and validation of a DNA-PfAgo detection system for gastric cancer high-risk factor Hp-VacA
Analytical Biochemistry · 2026-11 · 718 · 116202
DOI: 10.1016/j.ab.2026.116202 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Analytical Biochemistry, 2026-11. Verfasst von Jincen Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu University of Traditional Chinese Medicine, Wenjiang District, Chengdu, Sichuan, 611137, China. Hauptthemen laut MEDLINE: Helicobacter pylori, Bacterial Proteins, Stomach Neoplasms, Pyrococcus furiosus. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Sichuan Province Health Commission.
Abstract (Originalsprache)
Gastric carcinoma (GC) remains a leading cause of global cancer-related mortality, with Helicobacter pylori (Hp) infection identified as its primary risk factor. It is classified as a Group I carcinogen by the World Health Organization. Current Hp detection methods are limited by poor genotyping precision, high false-positive rates, and reliance on invasive sampling, which hinder early risk stratification. Here, we developed a molecular assay that integrates Recombinase Polymerase Amplification (RPA) and Pyrococcus furiosus Argonaute (PfAgo) for specific detection of the Hp virulence factor VacA. We designed RPA primers targeting conserved sequences of the ureA and vacA genes, followed by guide DNA (gDNA) and fluorescent probes. The one-tube RPA-PfAgo system was optimized using Hp genomic DNA, and its performance was validated with clinical saliva samples. The assay demonstrated a LOD of 10 copies/μL for both ureA and vacA, demonstrating a 10-fold higher sensitivity than quantitative PCR (qPCR, LOD = 102 copies/μL). Clinical validation (n = 26 identified saliva samples) showed 94.1% sensitivity and 100% specificity, enabling accurate differentiation of VacA-positive high-virulence strains. This method not only avoids invasive sampling but also reduces detection time to 50 minutes. The RPA-PfAgo assay provides a rapid, non-invasive tool for Hp screening and virulence typing, facilitating personalized GC risk assessment and clinical management. The established technical framework shows good scalability for other pathogen detection, public health surveillance, and food safety monitoring scenarios.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chengdu University of Traditional Chinese Medicine, Wenjiang District, Chengdu, Sichuan, 611137, China.
- Chengdu Hi-Tech Tianfu Medicine & Rehabilitation Center, Hi-Tech Zone, Chengdu, Sichuan, 610041, China.
- Chengdu University of Traditional Chinese Medicine, Wenjiang District, Chengdu, Sichuan, 611137, China. Electronic address: songzhen@cdutcm.edu.cn.
Förderung
- Sichuan Province Health Commission
Zitieren
APA
Li, J., Wu, T., Du, X., Chen, T., Yang, J., Xiong, H., & Song, Z. (2026). Development and validation of a DNA-PfAgo detection system for gastric cancer high-risk factor Hp-VacA. Analytical Biochemistry, 718, 116202. https://doi.org/10.1016/j.ab.2026.116202
Vancouver
Li J, Wu T, Du X, Chen T, Yang J, Xiong H, et al. Development and validation of a DNA-PfAgo detection system for gastric cancer high-risk factor Hp-VacA. Analytical Biochemistry. 2026;718:116202. doi:10.1016/j.ab.2026.116202
BibTeX
@article{Li2026,
author = {Li, Jincen and Wu, Ting and Du, Xuemei and Chen, Tingzhu and Yang, Jinyan and Xiong, Hui and Song, Zhen},
title = {Development and validation of a DNA-PfAgo detection system for gastric cancer high-risk factor Hp-VacA},
journal = {Analytical Biochemistry},
year = {2026},
volume = {718},
pages = {116202},
doi = {10.1016/j.ab.2026.116202}
}
EUVIMED